Kiora Pharmaceuticals, Inc.

NasdaqCM:KPRX Stock Report

Market Cap: US$11.7m

Kiora Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Kiora Pharmaceuticals has a total shareholder equity of $13.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $21.2M and $7.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$13.87m
EquityUS$13.93m
Total liabilitiesUS$7.29m
Total assetsUS$21.23m

Recent financial health updates

Recent updates

Analysis Article • May 21

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Shareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...
Seeking Alpha • Oct 13

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharmaceuticals (NASDAQ:KPRX) has received a letter from Nasdaq on October 12, 2022 informing the company that it has regained compliance with the minimum bid price requirement. Kiora was previously notified by Nasdaq on February 23, 2022 that it was not in compliance with the minimum bid price rule.
Seeking Alpha • Sep 26

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a biotech focused on treatments for eye disorders, announced Monday that the company’s shareholders authorized a reverse stock split of the common stock. Accordingly, the KPRX board has approved a decision to implement a reverse stock split of one share of common stock for every 40 shares, and the company shares will begin trading on Nasdaq on a split-adjusted basis on Sep. 27. KPRX shares added ~10% pre-market after the announcement. The reverse stock split is expected to reduce KPRX’s total outstanding common shares to ~1.1M with no impact on authorized shares and par value which will remain at 50M and $0.01, respectively. Kiora (KPRX) shares have plunged ~90% over the past 12 months underperforming the broader maker, as shown in this graph.
Seeking Alpha • Aug 12

Kiora Pharmaceuticals reports 1H results

Kiora Pharmaceuticals press release (NASDAQ:KPRX): 1H Net loss for the first half of 2022 was $6.0 million compared to $4.6 million for the first half of 2021. Cash and cash equivalents were $2.4 million as of June 30, 2022 with $1.1 million in prepaid expenses for research and development activities. Subsequent to the end of the first half, Kiora raised an additional $5.3 million in net proceeds from a public offering Shares +8.8% PM.
Seeking Alpha • Jul 28

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals (NASDAQ:KPRX) said it was granted a U.S. patent covering hydrogel-based sustained release platforms, including KIO-201, which helps in controlled release of antibiotics to treat eye diseases. The Salt Lake City-based company added that the patent — No. 11,376,214 — relates to non-blurring, antibiotic-containing hydrogel compositions which have an extended contact time on the eye and have potential to improve the health of the ocular surface for accelerated wound healing. Kiora noted that KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, formulated as an eye drop aimed to accelerate natural corneal wound healing. "In addition to potentially repairing corneal wounds as a standalone treatment, we see opportunities to employ our technology in combination with antibiotics to further accelerate wound healing and reduce post-surgical complications, including infections," said Kiora President and CEO Brian Strem.
Seeking Alpha • Jul 22

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora Pharmaceuticals (NASDAQ:KPRX) prices an underwritten public offering for gross proceeds of ~$5.2M prior to deducting underwriting discounts and commissions and offering expenses. Underwriters' have a 45-day option to purchase up to ~3.93M additional shares. Closing expected to take place on or about July 26, 2022.
Seeking Alpha • Jul 05

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals (NASDAQ:KPRX) said it enrolled the first patient as a part of a phase 2 trial of its eye drops KIO-201 to treat patients with Persistent Corneal Epithelial Defect (PCED). PCED is a rare ocular surface condition characterized by non-healing wounds on the eye surface. KIO-201 is a chemically modified form of the natural polymer hyaluronic acid aimed to accelerate natural corneal wound healing, according to the company's July 5 press release. The study will enroll 10 patients who will be evaluated at 28 days after receiving KIO-201 six times daily. The trial's goals are to evaluate safety and tolerability︎, and the percentage of patients with corneal healing and the associated time to healing.

Financial Position Analysis

Short Term Liabilities: KPRX's short term assets ($18.7M) exceed its short term liabilities ($2.8M).

Long Term Liabilities: KPRX's short term assets ($18.7M) exceed its long term liabilities ($4.5M).

Debt to Equity History and Analysis

Debt Level: KPRX is debt free.

Reducing Debt: KPRX has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KPRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KPRX has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 10.9% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/04 21:00
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kiora Pharmaceuticals, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC
Michael OkunewitchMaxim Group